Journal Article Reviews Oleandrin’s Antiviral Activity Against ‘Enveloped’ Viruses, Including its Ability to Inhibit the Virus that Causes COVID-19
The article states, The ability of oleandrin to inhibit the relative infectivity of progeny virus particles may offer a unique approach to treating certain viral diseases.
- The article states, The ability of oleandrin to inhibit the relative infectivity of progeny virus particles may offer a unique approach to treating certain viral diseases.
- This drug has been through both Phase I and Phase II trials (completed in 2016) in patients with malignant disease.
- The Journal of Experimental Pharmacology is a peer-reviewed, open access, online journal.
- Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.